X4 Pharmaceuticals, Inc. (XFOR): Price and Financial Metrics

X4 Pharmaceuticals, Inc. (XFOR): $1.00

-0.04 (-4.13%)

POWR Rating

Component Grades













Add XFOR to Watchlist
Sign Up

Industry: Biotech



in industry

XFOR Stock Price Chart Interactive Chart >

Price chart for XFOR

XFOR Price/Volume Stats

Current price $1.00 52-week high $2.41
Prev. close $1.04 52-week low $0.65
Day low $0.99 Volume 421,283
Day high $1.04 Avg. volume 805,716
50-day MA $1.08 Dividend yield N/A
200-day MA $1.28 Market Cap 69.03M

X4 Pharmaceuticals, Inc. (XFOR) Company Bio

X4 Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company specializes in developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases including primary immunodeficiencies and cancer. X4's oral small molecule drug candidates antagonize the CXCR4 pathway which plays a central role in immune surveillance.

XFOR Latest News Stream

Event/Time News Detail
Loading, please wait...

XFOR Latest Social Stream

Loading social stream, please wait...

View Full XFOR Social Stream

Latest XFOR News From Around the Web

Below are the latest news stories about X4 PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XFOR as an investment opportunity.

X4 Pharmaceuticals Inc. (XFOR) can excel with these strategies

In Friday’s session, X4 Pharmaceuticals Inc. (NASDAQ:XFOR) marked $0.93 per share, down from $0.99 in the previous session. While X4 Pharmaceuticals Inc. has underperformed by -6.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XFOR fell by -76.21%, with highs and lows ranging from $4.20 to […]

US Post News | December 12, 2022

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia Medical claims research defines an estimated 50,000 U.S. chronic neutropenia patient population; patient survey voices the significant unmet medical needs BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases

Yahoo | December 12, 2022

Looking For A Top Momentum Stock? Check Out X4 Pharmaceuticals Inc. (NASDAQ: XFOR)

X4 Pharmaceuticals Inc. (NASDAQ:XFOR) shares, rose in value on Friday, 12/09/22, with the stock price down by -6.06% to the previous day’s close as strong demand from buyers drove the stock to $0.93. Actively observing the price movement in the last trading, the stock closed the session at $0.99, falling within a range of $0.9157 … Looking For A Top Momentum Stock? Check Out X4 Pharmaceuticals Inc. (NASDAQ: XFOR) Read More »

Stocks Register | December 10, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday!

William White on InvestorPlace | December 7, 2022

X4 Pharmaceuticals stock dips after pricing $65M securities offering (NASDAQ:XFOR)

X4 Pharmaceuticals (XFOR) shares fell 9% premarket on Wednesday after the therapeutics firm priced an $65M securities offering.The offering includes 52.3M shares of its common…

Seeking Alpha | December 7, 2022

Read More 'XFOR' Stories Here

XFOR Price Returns

1-mo -14.53%
3-mo -44.44%
6-mo -21.88%
1-year -45.95%
3-year -88.69%
5-year -98.69%
YTD 0.70%
2022 -56.64%
2021 -64.39%
2020 -39.91%
2019 -23.13%
2018 -81.82%

Continue Researching XFOR

Want to see what other sources are saying about X4 Pharmaceuticals Inc's financials and stock price? Try the links below:

X4 Pharmaceuticals Inc (XFOR) Stock Price | Nasdaq
X4 Pharmaceuticals Inc (XFOR) Stock Quote, History and News - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6864 seconds.